Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamune for Kidney Angiomyolipomas in TSC or LAM
NCT00126672Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2005
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sirolimus in renal angiomyolipoma (AML), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate at 52 weeks. Started Dec 2005; status: completed.
02
Drugs
sirolimus
03
Conditions
renal angiomyolipoma (AML)
Beyond the preview
Go deeper on NCT00126672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126672.